From StructContinue beyond “Insulet’s Abbott connection comes with two hats”Back to the brief ↗Feed / AMGN

Amgen Inc.

AMGN

Healthcare · 442.53 +4.0% today

You’ve read what changed. Here’s whether the market is confirming it.

Partial group confirmationMarket checked 19 Aug, 15:55 GMT-4

Jodie situation report

Amgen Inc.'s move is spreading beyond its market group.

AMGN accounts for 9.0% of the group's measured movement across 7.5 effective names. all 12 measured members are rising in raw terms, but 9 of 12 SPY-adjusted paths align to the upside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#6 of 12 by movement share
Group movement share9.0%Absolute path energy—not portfolio weight
Relative path+1.34%aligned
Effective breadth7.5 / 12broad
Relative alignment9/12upside path · 2 counter-moving
Capital-flow agreement41%not yet clean
SEQUENCE READ

GILD, MRK, GSK moved materially before AMGN. AMGN crossed its material path threshold at 09:50 ET, 5 minutes after the first measured mover. HALO, EXEL, INCY followed.

What changed
  • Revenue increased 9.5% versus the comparable filing period.
EVIDENCE COVERAGE

11 of 15 members in Biopharmaceuticals and Care are active. 5 of 8 disclosed connections are confirming.

What would change this read
  • At least 10 of 15 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • SNY remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.

Watch this read

Who this business touches

The relationships behind AMGN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

REGNRegeneron Pharmaceuticals, Inc.competitorMay 1, 2026 ▾

“On March 9, 2026, Amgen responded to Regeneron’s 2024 Complaint, denying infringement and asserting counterclaims seeking declaratory judgment that the asserted patents are not infringed, invalid, and/or unenforceable, and counterclaims for Sherman Act (15 U.…”

AZNAstraZeneca PLCpartnerFeb 13, 2026 ▾

“AstraZeneca plc We are in a collaboration with AstraZeneca for the development and commercialization of TEZSPIRE.”

Depended on by

PODD21.0% of PODDcustomerMay 6, 2026 ▾

“21 Table of Contents Drug Delivery Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.”

Filing peers

AVRSYYGT

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 32 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

AMGN is currently a Early Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.